Are you over 18 and want to see adult content?
More Annotations
A complete backup of tarragonadigital.com
Are you over 18 and want to see adult content?
A complete backup of jardinmahoney.com
Are you over 18 and want to see adult content?
A complete backup of blackseafleet-21.com
Are you over 18 and want to see adult content?
A complete backup of zukunft-personal.com
Are you over 18 and want to see adult content?
Favourite Annotations
Anuncios clasificados gratis - Locanto™ República Dominicana
Are you over 18 and want to see adult content?
PubPeer - Search publications and join the conversation.
Are you over 18 and want to see adult content?
Gaming Community, Console gaming mods - XPG Gamesaves
Are you over 18 and want to see adult content?
Казино Вулкан онлайн играть бесплатно без регистрации в Casino Vulсan online
Are you over 18 and want to see adult content?
Family.blog – Get your subdomain of family.blog
Are you over 18 and want to see adult content?
Text
disease.
EXTREME HYPERTRIGLYCERIDEMIA MANAGED WITH INSULIN Case Studies Extreme hypertriglyceridemia managed with insulin Moe Thuzar, MBBS, MRCP (UK), FRACP*, Vasant V. Shenoy, MD, FRACP, Usman H. Malabu, FRCP, FACP, FRACP, THE EFFECT OF SSRIS ON TOTAL CHOLESTEROL LEVELS IN Major depression has been associated with early death as the result of cardiovascular mechanisms secondary to increased lipids and/or the metabolic syndrome. Psychiatric drugs have been implicated in deleterious effects on weight, lipids, and glucose. The 5HT2-D2 antagonists are especially damaging in this regard; a significant proportion of subjects have been reported to gain weight and TREATMENT WITH VOLANESORSEN (VLN) REDUCED TRIGLYCERIDES prescribed concomitant triglyceride-lowering medication. The extremely restrictive dietary guidelines also impact social relationships and activities with 82% of patients TABLE 4. DUTCH LIPID CLINIC NETWORK DIAGNOSTIC CRITERIA Table 4. Dutch Lipid Clinic Network diagnostic criteria for Familial Hypercholesterolemia1-3 Points Criteria Family history First-degree relative with known premature* coronary and vascular disease, OR 1 TABLE 3: SIMON BROOME DIAGNOSTIC CRITERIA FOR FAMILIAL Table 3: Simon Broome diagnostic criteria for Familial Hypercholesterolemia1 Definite Familial Hypercholesterolemia: Required laboratory = high cholesterol levels: HOME PAGE: JOURNAL OF CLINICAL LIPIDOLOGYHOMEARTICLES IN PRESSCURRENT ISSUELIST OF ISSUESSUPPLEMENTSPERMISSIONS The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal's readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as DRAMATIC LOWERING OF VERY HIGH LP(A) IN RESPONSE TO NIACIN7 We describe a patient with markedly elevated lipoprotein(a) (Lp(a)) without any other lipid abnormalities. After a myocardial infarction, she was treated with combination of extended-release niacin and statin. An 88% reduction in Lp(a) was observed during 5 years of treatment, which is much better response than usually reported. NATIONAL LIPID ASSOCIATION SCIENTIFIC STATEMENT ON THE USE Representatives from the National Lipid Association (NLA) participated in the development of the 2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterol, which reaffirmed that lifestyle changes and statin treatment are therapeutic cornerstones for atherosclerotic cardiovascular disease (ASCVD) risk reduction. A CLINICIAN'S GUIDE TO STATIN DRUG-DRUG INTERACTIONS The statins are widely used worldwide to reduce risk for cardiovascular events in both the primary and secondary prevention settings. Although generally quite safe, the statins can be associated with a variety of serious side adverse effects, including myalgia, myopathy, and changes in plasma enzymes of hepatic origin. Although rare, the most serious of these is rhabdomyolysis. CHYLOMICRONEMIA AND PANCREATITIS Chylomicronemia patients have low LDL-C, HDL-C, and Lp (a) levels, but relatively normal apoA-I and apoB levels. Moreover there are an estimated 38,000 cases of chylomicronemia with fasting triglyceride levels > 2,000 mg/dL in the United States. These subjects are at high risk of developing recurrent pancreatitis, a potentially fataldisease.
EXTREME HYPERTRIGLYCERIDEMIA MANAGED WITH INSULIN Case Studies Extreme hypertriglyceridemia managed with insulin Moe Thuzar, MBBS, MRCP (UK), FRACP*, Vasant V. Shenoy, MD, FRACP, Usman H. Malabu, FRCP, FACP, FRACP, THE EFFECT OF SSRIS ON TOTAL CHOLESTEROL LEVELS IN Major depression has been associated with early death as the result of cardiovascular mechanisms secondary to increased lipids and/or the metabolic syndrome. Psychiatric drugs have been implicated in deleterious effects on weight, lipids, and glucose. The 5HT2-D2 antagonists are especially damaging in this regard; a significant proportion of subjects have been reported to gain weight and TREATMENT WITH VOLANESORSEN (VLN) REDUCED TRIGLYCERIDES prescribed concomitant triglyceride-lowering medication. The extremely restrictive dietary guidelines also impact social relationships and activities with 82% of patients TABLE 4. DUTCH LIPID CLINIC NETWORK DIAGNOSTIC CRITERIA Table 4. Dutch Lipid Clinic Network diagnostic criteria for Familial Hypercholesterolemia1-3 Points Criteria Family history First-degree relative with known premature* coronary and vascular disease, OR 1 TABLE 3: SIMON BROOME DIAGNOSTIC CRITERIA FOR FAMILIAL Table 3: Simon Broome diagnostic criteria for Familial Hypercholesterolemia1 Definite Familial Hypercholesterolemia: Required laboratory = high cholesterol levels: CURRENT TRENDS IN NON–HDL CHOLESTEROL AND LDL CHOLESTEROL Low-density lipoprotein cholesterol (LDL-C) and non–high-density lipoprotein cholesterol (non–HDL-C) are targets for prevention of atherosclerotic cardiovascular disease (ASCVD). The American Heart Association and American College of Cardiology recently modified recommendations for clinical management of cholesterol in secondary and primary prevention. REVIEW OF CURRENT EVIDENCE AND CLINICAL RECOMMENDATIONS ON Historically, low-carbohydrate (CHO) and very-low-CHO diets have been used for weight loss. Recently, these diets have been promoted for type 2 diabetes (T2D) management. This scientific statement provides a comprehensive review of the current evidence base available from recent systematic reviews and meta-analyses on the effects of low-CHO and very-low-CHO diets on body LIPOPROTEIN APHERESIS FOR LIPOPROTEIN(A) AND Elevated lipoprotein(a) is an independent risk factor for cardiovascular disease (CVD). In the United States, lipoprotein apheresis (LA) therapy is approved for patients with familial hypercholesterolemia. Germany uses LA therapy for patients with an Lp(a) > 60 mg/dL, normal low-density lipoprotein cholesterol (LDL-C)levels, and CVD.
USE OF LIPID-LOWERING MEDICATIONS IN MYASTHENIA GRAVIS: A but significant complication of statin therapy.9 Furthermore, statins are known to aggravate MG and expose other under-lying neuromuscular conditions.10 Ezetimibe monotherapy has IS LOWER AND LOWER BETTER AND BETTER? A RE-EVALUATION OF Researchers from the Cholesterol Treatment Trialists' (CTT) Collaboration have argued for maximal lowering of low-density lipoprotein cholesterol (LDL-C) by the use of pharmacologic agents, with the strongest evidence coming from the five comparison statin studies in their second meta-analysis. The CTT meta-analysis has many strengths but also a number of limitations, which have not been A CLINICIAN'S GUIDE TO STATIN DRUG-DRUG INTERACTIONS Original Contribution A clinician’s guide to statin drug-drug interactions Kenneth A. Kellick, PharmD, FNLA*, Michael Bottorff, PharmD, FNLA, Peter P. Toth, MD, PhD UPDATE ON THE USE OF PCSK9 INHIBITORS IN ADULTS An Expert Panel convened by the National Lipid Association was charged with updating the recommendations on the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody therapy that were provided by the 2015 National Lipid Association Recommendations for the Patient-Centered Management of Dyslipidemia: Part 2. Recent studies have demonstrated the efficacy of these agents DIFFERENCE BETWEEN CALCULATED AND DIRECT-MEASURED LOW We evaluated factors that caused differences between calculated low-density lipoprotein cholesterol (C-LDL-C) and direct-measured LDL-C (D-LDL-C) and compared them in subjects with diabetes mellitus (DM) or taking lipid-lowering medications. PREVALENCE OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE Dr. Gorcyca is an employee of Sanofi. The MarketScan Research Database was utilized with inclusion criteria of 2013 LDL-C measurement (index), age ≥18 years, and evidence of the following high-risk conditions during two years pre-index: Recent acute coronary syndrome (ACS) within 12 months, stable coronary heart disease (CHD), ischemic stroke, peripheral arterial disease (PAD), or diabetes. CLASSIFICATION EXAMPLES OF GENETIC DISEASES* GENETIC *In addition to genetic causes, many of these hyperlipoproteinemias may be acquired or secondary to high carbohydrate diets, medications, and/or underlying diseases. HOME PAGE: JOURNAL OF CLINICAL LIPIDOLOGYHOMEARTICLES IN PRESSCURRENT ISSUELIST OF ISSUESSUPPLEMENTSPERMISSIONS The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal's readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as DRAMATIC LOWERING OF VERY HIGH LP(A) IN RESPONSE TO NIACIN7 We describe a patient with markedly elevated lipoprotein(a) (Lp(a)) without any other lipid abnormalities. After a myocardial infarction, she was treated with combination of extended-release niacin and statin. An 88% reduction in Lp(a) was observed during 5 years of treatment, which is much better response than usually reported. CURRENT TRENDS IN NON–HDL CHOLESTEROL AND LDL CHOLESTEROLLDL CHOLESTEROL LEVELSCHOLESTEROL LDL HDL RATIOHDL CHOLESTEROL LEVELS CHARTLDL AND HDLLDL HDL RATIO CHART Low-density lipoprotein cholesterol (LDL-C) and non–high-density lipoprotein cholesterol (non–HDL-C) are targets for prevention of atherosclerotic cardiovascular disease (ASCVD). The American Heart Association and American College of Cardiology recently modified recommendations for clinical management of cholesterol in secondary and primary prevention. NATIONAL LIPID ASSOCIATION SCIENTIFIC STATEMENT ON THE USENATIONAL LIPID ASSOCIATION 2020NATIONAL LIPID ASSOCIATION AGENDA Representatives from the National Lipid Association (NLA) participated in the development of the 2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterol, which reaffirmed that lifestyle changes and statin treatment are therapeutic cornerstones for atherosclerotic cardiovascular disease (ASCVD) risk reduction. CHYLOMICRONEMIA AND PANCREATITIS Chylomicronemia patients have low LDL-C, HDL-C, and Lp (a) levels, but relatively normal apoA-I and apoB levels. Moreover there are an estimated 38,000 cases of chylomicronemia with fasting triglyceride levels > 2,000 mg/dL in the United States. These subjects are at high risk of developing recurrent pancreatitis, a potentially fataldisease.
USE OF LIPID-LOWERING MEDICATIONS IN MYASTHENIA GRAVIS: ADRUGS THAT CAUSE MYASTHENIA GRAVISMEDS FOR MYASTHENIA GRAVISMYASTHENIA GRAVIS ANTIBIOTICSTRAMADOL AND MYASTHENIA GRAVIS Case Studies Use of lipid-lowering medications in myasthenia gravis: A case report and literature review SophieC.Ragbourne,BSc,MartinA.Crook,BSc,MBBS,MA,PhD,FRCPath STATIN UTILIZATION AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL , 100 mg/dL at follow-up.14 We also examined attainment of LCL-C , 70 mg/dL as this threshold is commonly applied in contemporary clinical practice for patients with ASCVD and was first recommended as anoptional goal
GENETIC TESTING IN DYSLIPIDEMIA: A SCIENTIFIC STATEMENT Preamble: The NLA position statement on genetic testing builds on prior NLA recommendations for the patient-centered management of dyslipidemia1,2 and pro- A CLINICIAN'S GUIDE TO STATIN DRUG-DRUG INTERACTIONS Original Contribution A clinician’s guide to statin drug-drug interactions Kenneth A. Kellick, PharmD, FNLA*, Michael Bottorff, PharmD, FNLA, Peter P. Toth, MD, PhD TREATMENT WITH VOLANESORSEN (VLN) REDUCED TRIGLYCERIDES prescribed concomitant triglyceride-lowering medication. The extremely restrictive dietary guidelines also impact social relationships and activities with 82% of patients HOME PAGE: JOURNAL OF CLINICAL LIPIDOLOGYHOMEARTICLES IN PRESSCURRENT ISSUELIST OF ISSUESSUPPLEMENTSPERMISSIONS The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal's readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as DRAMATIC LOWERING OF VERY HIGH LP(A) IN RESPONSE TO NIACIN7 We describe a patient with markedly elevated lipoprotein(a) (Lp(a)) without any other lipid abnormalities. After a myocardial infarction, she was treated with combination of extended-release niacin and statin. An 88% reduction in Lp(a) was observed during 5 years of treatment, which is much better response than usually reported. CURRENT TRENDS IN NON–HDL CHOLESTEROL AND LDL CHOLESTEROLLDL CHOLESTEROL LEVELSCHOLESTEROL LDL HDL RATIOHDL CHOLESTEROL LEVELS CHARTLDL AND HDLLDL HDL RATIO CHART Low-density lipoprotein cholesterol (LDL-C) and non–high-density lipoprotein cholesterol (non–HDL-C) are targets for prevention of atherosclerotic cardiovascular disease (ASCVD). The American Heart Association and American College of Cardiology recently modified recommendations for clinical management of cholesterol in secondary and primary prevention. NATIONAL LIPID ASSOCIATION SCIENTIFIC STATEMENT ON THE USENATIONAL LIPID ASSOCIATION 2020NATIONAL LIPID ASSOCIATION AGENDA Representatives from the National Lipid Association (NLA) participated in the development of the 2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterol, which reaffirmed that lifestyle changes and statin treatment are therapeutic cornerstones for atherosclerotic cardiovascular disease (ASCVD) risk reduction. CHYLOMICRONEMIA AND PANCREATITIS Chylomicronemia patients have low LDL-C, HDL-C, and Lp (a) levels, but relatively normal apoA-I and apoB levels. Moreover there are an estimated 38,000 cases of chylomicronemia with fasting triglyceride levels > 2,000 mg/dL in the United States. These subjects are at high risk of developing recurrent pancreatitis, a potentially fataldisease.
USE OF LIPID-LOWERING MEDICATIONS IN MYASTHENIA GRAVIS: ADRUGS THAT CAUSE MYASTHENIA GRAVISMEDS FOR MYASTHENIA GRAVISMYASTHENIA GRAVIS ANTIBIOTICSTRAMADOL AND MYASTHENIA GRAVIS Case Studies Use of lipid-lowering medications in myasthenia gravis: A case report and literature review SophieC.Ragbourne,BSc,MartinA.Crook,BSc,MBBS,MA,PhD,FRCPath STATIN UTILIZATION AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL , 100 mg/dL at follow-up.14 We also examined attainment of LCL-C , 70 mg/dL as this threshold is commonly applied in contemporary clinical practice for patients with ASCVD and was first recommended as anoptional goal
GENETIC TESTING IN DYSLIPIDEMIA: A SCIENTIFIC STATEMENT Preamble: The NLA position statement on genetic testing builds on prior NLA recommendations for the patient-centered management of dyslipidemia1,2 and pro- A CLINICIAN'S GUIDE TO STATIN DRUG-DRUG INTERACTIONS Original Contribution A clinician’s guide to statin drug-drug interactions Kenneth A. Kellick, PharmD, FNLA*, Michael Bottorff, PharmD, FNLA, Peter P. Toth, MD, PhD TREATMENT WITH VOLANESORSEN (VLN) REDUCED TRIGLYCERIDES prescribed concomitant triglyceride-lowering medication. The extremely restrictive dietary guidelines also impact social relationships and activities with 82% of patients NATIONAL LIPID ASSOCIATION RECOMMENDATIONS FOR PATIENT Original Articles National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary* Terry A. Jacobson, MD*, Matthew K. CLINICAL AND PATHOPHYSIOLOGICAL EVIDENCE SUPPORTING THE While the impact of very low concentrations of low–density lipoprotein cholesterol (LDL-C) on cardiovascular prevention is very reassuring, it is intriguing to know what effect these extremely low LDL-C concentrations have on lipid homoeostasis. The evidence supporting the safety of extremely low LDL levels comes from genetic studies and clinical drug trials. NATIONAL LIPID ASSOCIATION RECOMMENDATIONS FOR PATIENT National Lipid Association Recommendations - Part 2 National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2 CHYLOMICRONEMIA SYNDROME: FAMILIAL OR NOT? Chylomicronemia syndrome (CS) is a metabolic condition characterized by severely elevated plasma triglycerides (>880 mg/dL) and high rates of morbidity and mortality. The syndrome can be classified into two major groups: monogenic familial chylomicronemia syndrome (FCS) and multifactorial chylomicronemia syndrome (MCS), the frequencies of which are ill-defined. A CLINICIAN'S GUIDE TO STATIN DRUG-DRUG INTERACTIONS The statins are widely used worldwide to reduce risk for cardiovascular events in both the primary and secondary prevention settings. Although generally quite safe, the statins can be associated with a variety of serious side adverse effects, including myalgia, myopathy, and changes in plasma enzymes of hepatic origin. Although rare, the most serious of these is rhabdomyolysis. EFFECTS OF FREE OMEGA-3 CARBOXYLIC ACIDS AND FENOFIBRATE Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, REVIEW OF RED YEAST RICE CONTENT AND CURRENT FOOD AND DRUG Red yeast rice (RYR) is a commonly used dietary supplement for the management of dyslipidemia. In 2007, the Food and Drug Administration (FDA) issued a consumer warning to avoid RYR products because they may contain unauthorized drug (lovastatin) and also implemented Current Good Manufacturing Practices (CGMP) requiring that proper controls be in place by dietary supplement TRIGLYCERIDES AND CARDIOVASCULAR DISEASE Series 626 www.thelancet.com Vol 384 August 16, 2014 Lipids and cardiovascular disease 3 Triglycerides and cardiovascular disease Børge G Nordestgaard, Anette Varbo After the introduction of statins, clinical emphasis fi rst focussed on LDL cholesterol-lowering, thenon the potential
NATIONAL LIPID ASSOCIATION ANNUAL SUMMARY OF CLINICAL Original Contribution National Lipid Association Annual Summary of Clinical Lipidology 2015 Harold E. Bays, MD, FTOS, FACC, FACE, FNLA*, Peter H. Jones, MD, FACP, FNLA, TABLE 4. DUTCH LIPID CLINIC NETWORK DIAGNOSTIC CRITERIA Table 4. Dutch Lipid Clinic Network diagnostic criteria for Familial Hypercholesterolemia1-3 Points Criteria Family history First-degree relative with known premature* coronary and vascular disease, OR 1*
*
*
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0